Wide Analyst Gap Signals Uncertainty as BioNTech Prepares Cancer Drug Data

BioNTech shareholders approve board changes with 92% support, but stock falls 2.22%. Upcoming ASCO readout for Pumitamig in lung cancer could determine pipeline credibility.

BioNTech’s shareholders have given management a ringing endorsement. At the annual general meeting on 15 May, 92% of the voting capital was represented, and every resolution passed — including the expansion of the supervisory board to eight members. Iris Löw-Friedrich and Susanne Schaffert join the panel, bringing late-stage clinical development experience, while Helmut Jeggle remains chairman. Yet the stock market has greeted this unanimity with open suspicion: the shares closed at €76.95 on Friday, down 2.22%, and have shed 8.01% over the past month. The equity now trades roughly 24% below its 52-week high and languishes more than 11% beneath the 200-day moving average.

The next real test, however, is clinical, not structural. At the American Society of Clinical Oncology (ASCO) conference later this month, BioNTech will unveil Phase 2 data from its ROSETTA-Lung-02 study. The spotlight falls on Pumitamig, a candidate administered alongside chemotherapy in a head-to-head comparison against the established immunotherapy Pembrolizumab in lung cancer patients. While the company is running multiple Phase 3 trials and recently launched a global breast cancer study as part of its transformation into an oncology specialist, the ASCO readout is expected to provide the first concrete evidence that its hefty R&D spend is paying off.

The financial backdrop underscores the urgency. First-quarter revenue slid to €118.1 million from €182.8 million a year earlier, illustrating how sharply the revenue mix has shifted away from Covid-related products. Management is sticking with its full-year guidance of $2.3 billion to $2.6 billion in total revenue, and is simultaneously executing a share buyback programme of up to $1.0 billion. The company’s ability to sustain such an ambitious research agenda hinges on its pipeline delivering tangible results.

Wall Street analysts are deeply divided on the stock’s prospects. The average price target sits around $131, implying considerable upside from current levels, but the range is exceptionally wide. Canaccord Genuity retains a Buy rating with a $158 target, while Leerink takes a more cautious stance at $94. Berenberg recently trimmed its own target, though it still argues the shares are heavily undervalued. This dispersion reflects the binary nature of the upcoming ASCO data: convincing efficacy could re-rate the stock, while underwhelming results would reinforce the market’s scepticism.

With the ASCO presentation scheduled for late May and second-quarter earnings due in August, investors now face a clear sequence of catalysts. The annual meeting has reaffirmed the board’s strategic direction, but the shares are technically bruised and in need of a positive surprise. All eyes are on Pumitamig to supply that surprise — or to confirm that the road ahead remains uphill.